AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06098833
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life (dose 1=2mg/kg/dose, dose 2=2.5mg/kg/dose, and doses 3-14=3mg/kg/dose)
Trial: NCT05052996
Drug: LEN
RxNorm normalized name: LENS
DrugBank: Scutellaria baicalensis root (DB14364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food
Trial: NCT06315920
Drug: Parecoxib
RxNorm normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Single dose of 40mg of IV Parecoxib.
Trial: NCT06315920
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 5 mg of IV Morphine.
Trial: NCT05030675
Drug: Fostamatinib
RxNorm normalized name: FOSTAMATINIB
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT05457959
Drug: Poly ICLC
RxNorm normalized name: Poly iclc
DrugBank: Hiltonol (DB17293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT05258071
Drug: Pirepemat
RxNorm normalized name: Pirepemat
DrugBank: Pirepemat (DB19165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral use
Trial: NCT06532162
Drug: 1% Lidocaine Paracervical Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 22-gauge spinal needle will be loaded with 10 mL of 1% lidocaine with epinephrine.~The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Trial: NCT06532162
Drug: Normal Saline Paracervical Injection
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 22-gauge spinal needle will be loaded with 10 mL of normal saline. The injection will be instilled slowly over 60 seconds into the cervicovaginal junction in two equal areas at 2 and 10 o'clock. The injection is continuous from superficial to deep (3 cm).
Trial: NCT05721755
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05721755
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05721755
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT05745064
Drug: TL-925
RxNorm normalized name: Thallous chloride Tl 201
DrugBank: Thallous chloride Tl-201 (DB16624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TL-925 is an eye drop.
Trial: NCT06444880
Drug: Ubamatamab
RxNorm normalized name: Ubamatamab
DrugBank: Ubamatamab (DB18875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06444880
Drug: Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by IV
Trial: NCT04605081
Drug: Naltrexone and Bupropion (NB) medication
RxNorm normalized name: bupropion and naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NB medication will be taken daily in pill form.
Trial: NCT05986422
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment period consists of six weeks of daily intake of either Methylprednisolone or placebo (depending on randomization), followed by an additional six weeks of daily intake of open-label Methylprednisolone. During the study, follow-up assessments will be conducted at two points: at week 8 and week 20 from the start of each treatment phase.
Trial: NCT06325566
Drug: Rexlemestrocel-L + HA mixture
RxNorm normalized name: brown mixture
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rexlemestrocel-L will be combined in 1:1 by-volume ratio with HA solution and the resulting mixture will be administered as intradiscal injection.
Trial: NCT06325566
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution injection adjacent to the index disc.
Trial: NCT05603143
Drug: Obeldesivir
RxNorm normalized name: Obeldesivir
DrugBank: Obeldesivir (DB18821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally without regard to food.
Trial: NCT05603143
Drug: Obeldesivir Placebo
DrugBank: Obeldesivir (DB18821)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered orally without regard to food.
Trial: NCT06082271
Drug: Cortisone
RxNorm normalized name: Cortisone
DrugBank: Cortisone acetate (DB01380)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DEPO-MEDROL 40 mg/ml + 1 cc di NAROPINA 0,75% 7,5 mg/ml
Trial: NCT05929755
Drug: Depo-Medrol
RxNorm normalized name: DEPO-Medrol
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: steroid
Trial: NCT06043817
Drug: STX-721 (Escalated)
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STX-721 dose will be escalated per cBLRM-design.
Trial: NCT06043817
Drug: STX-721 (2 doses)
RxNorm normalized name: STX-100
DrugBank: STX-100 (DB16334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive STX-721 at one of two doses.
Trial: NCT06043817
Drug: STX-721 (RP2D)
RxNorm normalized name: STX-100
DrugBank: STX-100 (DB16334)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the RP2D of STX-721.
Trial: NCT06442423
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin will be administered in an opaque, size 2 gelatin capsule with approximately 180 ml of water to be orally ingested at Visit 5. The dose of psilocybin will be 25 mg.This is an open-label clinical trial with a single treatment arm. This is an open-label clinical trial with no blinding.
Trial: NCT05492318
Drug: Givinostat 10 mg/mL
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL oral suspension. Givinostat 10 mg/ml oral suspension was administered once, in the morning, in Days 1, 2, 6, 7, 17 and 18), and twice a day (50 mg as oral suspension), in the morning and in the evening, from the Day 4 to Day 18. On Day 19, only the morning dose was administered.
Trial: NCT05492318
Drug: Midazolam 1mg/ml IV
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam 1 mg/ml, solution for intravenous administration. Midazolam 1mg/ml IV, single dose, was administered on Days 1, 6 and 17, 1 hour after the planned morning time of givinostat administration. Midazolam IV were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Trial: NCT05492318
Drug: Midazolam 2.5 mg oromucosal solution
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 2.5 mg oromucosal solution. Midazolam 2.5 mg single oral solution was administered on Days 2, 7 and 18, 1 hour after the planned morning time of givinostat administration.~Oral midazolam (and dabigatran etexilate) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose.~Oral midazolam (and dabigatran etexilate) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before midazolam and dabigatran dosing until 2 hours postdose. Water was provided ad libitum at all other times. Midazolam (and dabigatran etexilate) were administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Trial: NCT05492318
Drug: Dabigatran etexilate 75 mg oral hard capsules
RxNorm normalized name: dabigatran etexilate 75 MG
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose: 75 mg; Dosage form: hard capsules On Days 1, 6 and 17, dabigatran etexilate 75 mg was administered (with midazolam 1mg IV) 1 hour after the planned morning time of givinostat administration.~Dabigatran etexilate (and midazolam) was administered following an overnight fasting of at least 8 hours and subjects remained fasted until at least 3 hours post-dose Oral dabigatran etexilate (and oral midazolam) was administered with 150 mL of water. Except for water given with the investigational products, no fluids were allowed from 1 hour before dabigatran (and midazolam) dosing until 2 hours postdose. Water was provided ad libitum at all other times. Dabigatran etexilate (and Midazolam) was administered with the subjects in a semi-recumbent position. Subjects remained semirecumbent until at least 3 hours post-dose.
Trial: NCT05486117
Drug: Delgocitinib
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cream for topical application 20 mg/g
Trial: NCT05766709
Drug: Semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Semaglutide will be administered subcutaneously once weekly.
Trial: NCT05766709
Drug: NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NNC0194-0499/Semaglutide A (40/3.20 mg/mL) co-formulation product will be administered subcutaneously once weekly.
Trial: NCT05766709
Drug: NNC0194-0499/Semaglutide A (40/0.33mg/mL)
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NNC0194-0499/Semaglutide A (40/0.33mg/mL) will be administered subcutaneously once weekly.
Trial: NCT06507618
Drug: Tamoxifen, Letrozole, Anastrozole, or Exemestane
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Choice and dose of neoadjuvant endocrine therapy at the discretion of the treating medical oncologist.
Trial: NCT06227221
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive sorafenib 400mg once daily. Insulin therapy will be continued as a routine therapy.
Trial: NCT04697810
Drug: Namodenoson
RxNorm normalized name: Namodenoson
DrugBank: Namodenoson (DB12885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg q12hours x 36 weeks
Trial: NCT05861687
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered once a day per-oral (PO) with the dose of 0.4 mg/kg
Trial: NCT05861687
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg
Trial: NCT05861687
Drug: Amoxicillin
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered thrice a day per-oral (PO) with the dose of 25 mg/kg
Trial: NCT05388760
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.
Trial: NCT06448286
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT05436223
Drug: Human CD19Targeted T Cells Injection
RxNorm normalized name: tisagenlecleucel
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of predetermined level CAR-positive T cells will be infused.
Trial: NCT04769050
Drug: Docetaxel combined with Trastuzumab±Pertuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w
Trial: NCT05609370
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously.
Trial: NCT05609370
Drug: Bevacizumab or Bevacizumab biosimilar
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05609370
Drug: 5-Fluorouracil
RxNorm normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered in accordance with relevant local guidelines and/or prescribing information
Trial: NCT06044337
Drug: BIIB059 (litifilimab)
RxNorm normalized name: Immunoglobulin g1, anti-(human blood dendritic cell antigen 2) (human-mus musculus monoclonal biib059 .gamma.1-chain), disulfide with human-mus musculus monoclonal biib059 .kappa.-chain, dimer
DrugBank: Litifilimab (DB18864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05438290
Drug: DPCP
RxNorm normalized name: DPCPX
DrugBank: DPCPX (DB12946)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical immunomodulator
Trial: NCT05362487
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide
Trial: NCT04713969
Drug: Pantoprazole 40mg
RxNorm normalized name: pantoprazole 40 MG
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40mg twice daily
Trial: NCT04893434
Drug: Gadobutrol
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will undergo 3 Gadavist injections. The intravenous injection of the GBCA Gadobutrol (Gadavist, Bayer Healthcare) at 0.1 mL/kg body weight (0.1 mmol/kg), administered as a bolus at a flow rate of approximately 2 mL/s. Each volunteer will undergo 1 and each patient 2 research Gadobutrol injections (the 3 injections mentioned in the protocol for patients is to account for the fact they will have had 1 injection as part of their standard of care, but the study only includes 2 research injections).
Trial: NCT06800729
Drug: TIX100, an orally available inhibitor of thioredoxin-interacting protein
DrugBank: Thioredoxin (DB11298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TIX100, an orally available inhibitor of thioredoxin-interacting protein
Trial: NCT05378464
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Trial: NCT05378464
Drug: Pepinemab
RxNorm normalized name: Pepinemab
DrugBank: Pepinemab (DB15155)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Trial: NCT05394337
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT05394337
Drug: Tiragolumab
RxNorm normalized name: Tiragolumab
DrugBank: Tiragolumab (DB16409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT04873362
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.
Trial: NCT04873362
Drug: Trastuzumab Emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.
Trial: NCT04873362
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
Trial: NCT06381570
Drug: Tovorafenib
RxNorm normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tovorafenib for oral dosing is provided as an immediate-release tablet in 100 mg strength. The 100 mg tablets are red to yellowish red oval tablets. All products are labeled tovorafenib. In addition, tovorafenib is provided as a powder for reconstitution (PfR) in bottles (430mg per bottle to deliver 300 mg dose). Upon reconstitution with water, the concentration is 25 mg/mL.~Vinblastine is administered by intravenous route as IV push, sites to follow local administration guidelines, once weekly (central line, but peripheral line is also permitted)
Trial: NCT05397600
Drug: Bimatoprost Ophthalmic
RxNorm normalized name: bimatoprost ophthalmic
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eyedrops
Trial: NCT06382467
Drug: Remimazolam besylate + propofol MCT
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: remimazolam besylate 3mg/kg/hr for induction, and 0.5 mg/kg/hr for maintenance + propofol MCT 1-4 mcg/ml using target-controlled infusion
Trial: NCT06382467
Drug: Propofol MCT
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol MCT 2-8 mcg/ml using target-controlled infusion
Trial: NCT05126277
Drug: ianalumab s.c. q4w
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab s.c. q4w in addition to SoC
Trial: NCT05126277
Drug: ianalumab s.c. q12w
DrugBank: Ianalumab (DB16666)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ianalumab s.c. q12w in addition to SoC
Trial: NCT06801054
Drug: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
RxNorm normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will receive a second dose of tenecteplase.
Trial: NCT05547100
Drug: LYBALVI
RxNorm normalized name: Lybalvi
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg Olanzapine/10 mg Samidorphan dose approved for use in treatment for schizophrenia and bipolar I disorder
Trial: NCT05935215
Drug: Iptacopan
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open Label
Trial: NCT05944016
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin (standard dose 10 mg p.o. once daily)
Trial: NCT05562297
Drug: sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients firstly receive sintilimab 200 mg (iv, 30 minutes) on day 1 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Trial: NCT05562297
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients firstly receive nab-paclitaxel 125 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Trial: NCT05562297
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients secondly receive gemcitabine 1000 mg/m\^2 (iv, 30 minutes) on days 1, and 8 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 3 circles in the absence of disease recurrence or unacceptable toxicity.
Trial: NCT05124431
Drug: Anlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib hydrochloride is a multi-target receptor tyrosine kinase inhibitor.
Trial: NCT05124431
Drug: everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg po，qd
Trial: NCT06425133
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For the first cycle: Regorafenib will be administered according to the REDOS schedule: week 1: 80 mg regorafenib daily week 2: 120 mg regorafenib daily week 3: 160 mg regorafenib daily week 4 : OFF. For the following cycles: regorafenib will be administered at 160mg in the absence of significant toxicity during cycle 1 or at a 80/120mg daily dose according to toxicity observed with the last dose used in the first cycle.
Trial: NCT05018481
Drug: Sodium Hyaluronate
RxNorm normalized name: sodium hyaluronate
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate of molecular weight 35kDa will be given in capsule form to study participants
Trial: NCT05191225
Drug: RiTUXimab Injection [Truxima]
RxNorm normalized name: rituximab Injection [Truxima]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 (mg/m2) / 60 minutes
Trial: NCT05288205
Drug: JAB-21822
RxNorm normalized name: JAB-21822
DrugBank: JAB-21822 (DB17478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KRAS G12C inhibitor
Trial: NCT05191225
Drug: RiTUXimab Injection [Truxima]
RxNorm normalized name: rituximab Injection [Truxima]
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 (mg/m2) / 30 minutes
Trial: NCT05288205
Drug: JAB-3312
RxNorm normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHP2 inhibitor